Atossa Therapeutics, Inc. Common Stock
ATOSAtossa Therapeutics, Inc. (ATOS) is a biotechnology company focused on developing targeted treatments for breast cancer, hormone-related issues, and other serious medical conditions. The company is particularly known for its research into novel therapies involving breast health and hormone modulation, aiming to address unmet medical needs through innovative drug delivery methods and clinical development efforts.
Company News
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...
Atossa Therapeutics reported Q1 2026 results with total operating expenses of $9.9 million, up $2.5 million year-over-year. The company advanced its lead candidate (Z)-endoxifen across oncology and rare disease indications, securing FDA Orphan Drug Designation for DMD and Rare Pediatric Disease designations for both DMD and McCune-Albright Syndro...
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising ca...
Atossa Therapeutics' CEO Dr. Steven Quay will participate in a fireside chat at the 27th Annual H.C. Wainwright Global Investment Conference, discussing clinical progress of their lead product (Z)-endoxifen, a potential breast cancer treatment and prevention therapy.
Atossa Therapeutics, a clinical-stage biopharmaceutical company, announced that its Vice President of Investor and Public Relations will participate in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit.
